就诊依从性与新生血管性年龄相关性黄斑变性视力结局的关联
该研究为CATT随机临床试验的二次分析,纳入美国44个中心1178例新生血管性年龄相关性黄斑变性患者,采用4种就诊依从性指标评估其与早期糖尿病视网膜病变研究视力(ETDRS VA)变化的关系。在控制协变量后,平均就诊间隔与最长就诊间隔均延迟或严重延迟者视力字母数减少更明显,提示就诊依从性与视力结局相关。
要点
- 就诊延迟越多,视力下降越明显,应将就诊依从性作为眼底病随访管理重点。
- 平均间隔与最长间隔延迟均与视力结局相关,提示需减少就诊负担同时保障随访。
- 该证据来自CATT试验二次分析,外推至真实世界仍需谨慎。
核心结论
- 就诊依从性与新生血管性年龄相关性黄斑变性患者的视力结局相关,延迟就诊者视力字母数减少更明显。
研究设计与样本
- CATT随机临床试验二次分析,2008年2月至2009年12月从美国44个临床中心招募年龄相关性黄斑变性患者,共1178例,平均(SD)年龄79.1(7.3)岁,727例(61.7%)为女性。
- 2年研究方案要求每4周1次就诊(每21-35天,共26次),比较贝伐珠单抗与雷珠单抗的每月给药与按需(pro re nata)治疗方案。
- 采用4种就诊依从性指标:总漏访次数、每次就诊平均间隔天数、最长就诊间隔天数、就诊恒定性(每3个月至少就诊1次的计数),并将平均与最长间隔分为准时(28-35天)、延迟(36-60天)和严重延迟(>60天)。
- 主要结局为基线至末次访视的ETDRS视力变化,采用线性多变量回归控制年龄、性别、基线视力、抗VEGF药物、注射次数和给药方案。
主要发现
- 平均(SD)漏访次数为2.4(3.1),1091例(92.6%)在整个研究期间就诊恒定性完整。
- 平均间隔分类中1060例(90.0%)为准时、108例(9.2%)为延迟、10例(0.8%)为严重延迟;最长间隔分类中197例(16.7%)为准时、773例(65.6%)为延迟、208例(17.7%)为严重延迟。
- 控制协变量后,延迟组(平均间隔=-6.1;最长间隔=-2.0)与严重延迟组(平均间隔=-12.5;最长间隔=-5.9)在平均和最长间隔类别中视力字母数均少于准时组(P < .001)。
关键数值与推荐
- 就诊准时定义为平均或最长就诊间隔28-35天,延迟为36-60天,严重延迟为>60天。
- 控制协变量后,延迟组平均间隔对应视力变化-6.1个字母、最长间隔对应-2.0个字母,严重延迟组分别为-12.5和-5.9个字母(P < .001)。
- 研究方案要求每4周1次就诊(每21-35天,共26次)。
临床怎么用
- 在新生血管性年龄相关性黄斑变性抗VEGF治疗随访中,应重视就诊依从性,尽量减少延迟就诊。
- 可考虑减少就诊负担但不损害视力结局的治疗策略,以提升随访依从性。
局限性
- 本文为CATT随机临床试验的二次分析,结果解释受原始试验设计与人群限制。
- 摘要未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Visit adherence has been shown to play a significant role in patient health outcomes. The effect of missing visits on visual acuity (VA) in individuals with neovascular age-related macular degeneration has yet to be characterized. OBJECTIVE: To quantify the association between patients' adherence to randomized clinical trial visits and VA in individuals with neovascular age-related macular degeneration based on 4 visit adherence metrics. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial randomized clinical trial. Individuals with age-related macular degeneration were recruited from 44 clinical centers in the United States between February 2008 and December 2009. The 2-year study protocol required 1 visit every 4 weeks (every 21-35 days for a total of 26 visits) for monthly vs pro re nata treatments of bevacizumab vs ranibizumab. Analysis took place from November 2018 through May 2019. EXPOSURES: Visit adherence was measured in 4 ways: total number of missed visits, average number of days (avg days) between each visit, longest duration in days (max days) between visits, and visit constancy (the tally of 3-month periods with at least 1 visit attended). Average and max days were also categorized as on time (28-35 days), late (36-60 days), and very late (>60 days). MAIN OUTCOMES AND MEASURES: Change in Early Treatment Diabetic Retinopathy Study VA between the baseline and the last visit. Linear multivariate regression models were applied to analyze the association between visit adherence and change in VA, controlling for age, sex, baseline VA, anti-vascular endothelial growth factor drug, number of injections, and dosing regimen. RESULTS: Of 1178 patients, the mean (SD) age was 79.1 (7.3) years, and 727 (61.7%) were women. The mean (SD) number of missed visits was 2.4 (3.1). Overall, 1091 patients (92.6%) had complete visit constancy during the entire study period. Average days were categorized with 1060 patients (90.0%) classified as on time, 108 (9.2%) were late, and 10 (0.8%) were very late. For max days between visits, 197 patients (16.7%) were on time, 773 (65.6%) were late, and 208 (17.7%) were very late. After controlling for covariates, the late (avg days = -6.1; max days = -2.0) and very late (avg days = -12.5; max days = -5.9) groups saw fewer letters in both the avg and max days categories than patients in the on-time group (P < .001). CONCLUSIONS AND RELEVANCE: These results provide evidence to support the concept that visit adherence contributes to VA outcomes in neovascular age-related macular degeneration. The magnitude of the association of visit adherence with VA outcomes in this clinical scenario suggests that substantial effort should be expended to strive for visit adherence or therapeutic strategies that reduce the visit burden without compromising VA outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00593450.
引用
- Ramakrishnan MS, Yu Y, VanderBeek BL, et al. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial. JAMA Ophthalmol. 2020. PMID: 32027349. doi:10.1001/jamaophthalmol.2019.4577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。